Literature DB >> 11792748

Effects of age and human papilloma viral load on colposcopy triage: data from the randomized Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesion Triage Study (ALTS).

Mark E Sherman1, Mark Schiffman, J Thomas Cox.   

Abstract

BACKGROUND: Testing for oncogenic human papillomavirus (HPV) DNA at a 1.0-pg/mL threshold represents a promising approach for colposcopy triage of atypical squamous cells of undetermined significance (ASCUS), but not for low-grade squamous intraepithelial lesions (LSIL). Considering age or viral load could improve colposcopy triage.
METHODS: We determined the sensitivity for detecting Cervical Intraepithelial Neoplasia 3 (CIN3) and cancer and the percentage of referrals for colposcopy using HPV testing and repeat thin-layer cytopathology in 2198 women with ASCUS and in 848 women with LSIL enrolled in ALTS from November 1996 through December 1998. We analyzed results by age and at two thresholds for HPV load and repeat cytopathology.
RESULTS: For ASCUS, the overall sensitivity of HPV testing at 1.0 pg/mL was 96.1% (95% confidence interval [CI] = 92.8 to 99.5%) and varied minimally with age (range, 93.9% to 97.8%). HPV testing at this threshold would refer 31.2% (95% CI = 28.0% to 34.3%) of women aged 29 years or older as compared with more than 65% of younger women. Among women aged 29 years or older with ASCUS, referral for repeat cytopathology of ASCUS had a sensitivity of 90.9% (95% CI = 81.1% to 100.0%) and would refer 50.1% (95% CI = 46.7 to 53.5%). Among all ASCUS, HPV testing using a 10.0-pg/mL threshold decreased sensitivity to 91.5% and referrals to 41.7%. More than 63% of LSIL would have been referred using any strategy achieving 90% sensitivity.
CONCLUSION: For women with ASCUS, HPV testing was highly sensitive for detecting CIN3 and cancer with dramatically fewer referrals of older women. Neither a single HPV test nor repeat cytopathology provides useful triage for women with LSIL.

Entities:  

Mesh:

Year:  2002        PMID: 11792748     DOI: 10.1093/jnci/94.2.102

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  36 in total

1.  Policy implications of adjusting randomized trial data for economic evaluations: a demonstration from the ASCUS-LSIL Triage Study.

Authors:  Nicole G Campos; Philip E Castle; Mark Schiffman; Jane J Kim
Journal:  Med Decis Making       Date:  2011-12-06       Impact factor: 2.583

2.  Cervical cancer mortality by neighbourhood income in urban Canada from 1971 to 1996.

Authors:  Edward Ng; Russell Wilkins; Michael Fung Kee Fung; Jean-Marie Berthelot
Journal:  CMAJ       Date:  2004-05-11       Impact factor: 8.262

3.  Atypical squamous cells of undetermined significance in patients with HPV positive DNA testing and correlation with disease progression by age group: an institutional experience.

Authors:  Erika F Rodriguez; Jordan P Reynolds; Sarah M Jenkins; Stephanie M Winter; Michael R Henry; Aziza Nassar
Journal:  Int J Clin Exp Pathol       Date:  2012-05-23

4.  Detection of TERC amplification in cervical epithelial cells for the diagnosis of high-grade cervical lesions and invasive cancer: a multicenter study in China.

Authors:  Jing Jiang; Li-Hui Wei; Ya-Li Li; Rui-Fang Wu; Xing Xie; You-Ji Feng; Guo Zhang; Chao Zhao; Yun Zhao; Zhong Chen
Journal:  J Mol Diagn       Date:  2010-09-23       Impact factor: 5.568

5.  Comparison of the GenoFlow human papillomavirus (HPV) test and the Linear Array assay for HPV screening in an Asian population.

Authors:  Oscar Gee-Wan Wong; C K Lo; Joanne N K Chow; Obe K L Tsun; Elaine Szeto; Stephanie S Liu; Hextan Y S Ngan; Annie N Y Cheung
Journal:  J Clin Microbiol       Date:  2012-02-15       Impact factor: 5.948

6.  The laboratory diagnosis of genital human papillomavirus infections.

Authors:  François Coutlée; Danielle Rouleau; Alex Ferenczy; Eduardo Franco
Journal:  Can J Infect Dis Med Microbiol       Date:  2005-03       Impact factor: 2.471

Review 7.  How to evaluate emerging technologies in cervical cancer screening?

Authors:  Marc Arbyn; Guglielmo Ronco; Jack Cuzick; Nicolas Wentzensen; Philip E Castle
Journal:  Int J Cancer       Date:  2009-12-01       Impact factor: 7.396

8.  Comparison of GP5+/6+-PCR and SPF10-line blot assays for detection of high-risk human papillomavirus in samples from women with normal cytology results who develop grade 3 cervical intraepithelial neoplasia.

Authors:  A T Hesselink; M A P C van Ham; D A M Heideman; Z M A Groothuismink; L Rozendaal; J Berkhof; F J van Kemenade; L A F G Massuger; W J G Melchers; C J L M Meijer; P J F Snijders
Journal:  J Clin Microbiol       Date:  2008-08-06       Impact factor: 5.948

9.  Detection of telomerase, its components, and human papillomavirus in cervical scrapings as a tool for triage in women with cervical dysplasia.

Authors:  N Reesink-Peters; M N Helder; G B A Wisman; A J Knol; S Koopmans; H M Boezen; E Schuuring; H Hollema; E G E de Vries; S de Jong; A G J van der Zee
Journal:  J Clin Pathol       Date:  2003-01       Impact factor: 3.411

10.  Age-specific prevalence of HPV genotypes in cervical cytology samples with equivocal or low-grade lesions.

Authors:  S Brismar-Wendel; M Froberg; A Hjerpe; S Andersson; B Johansson
Journal:  Br J Cancer       Date:  2009-07-21       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.